Related Experiment Video
Updated: Mar 18, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
The steady progress of targeted therapies, promising advances for lung cancer
Lorenzo Bombardelli1, Anton Berns2
1Division of Molecular Genetics, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Abstract:
Lung cancer remains one of the most complex and challenging cancers, being responsible for almost a third of all cancer deaths. This grim picture seems however to be changing, for at least a subset of lung cancers. The number of patients who can benefit from targeted therapies is steadily increasing thanks to the progress made in identifying actionable driver lesions in lung tumours. The success of the latest generation of EGFR and ALK inhibitors in the clinic not only illustrates the value of targeted therapies, but also shows how almost inevitably drug resistance develops. Therefore, more sophisticated approaches are needed to achieve long-term remissions. Although there are still significant barriers to be overcome, technological advances in early detection of relevant mutations and the opportunity to test new drugs in predictive preclinical models justify the hope that we will overcome these obstacles.
Insights
Lung cancer targeted therapies are improving, offering new hope for patients. However, drug resistance necessitates advanced strategies for long-term remission in lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Advancements in identifying actionable driver mutations are expanding targeted therapy options.
- Drug resistance is a significant challenge limiting the long-term efficacy of targeted lung cancer treatments.
Purpose of the Study:
- To review the progress and challenges in targeted therapies for lung cancer.
- To highlight the development of drug resistance and the need for advanced therapeutic strategies.
- To discuss the potential of new technologies in overcoming therapeutic barriers.
Main Methods:
- Review of current literature on lung cancer targeted therapies.
- Analysis of the impact of EGFR and ALK inhibitors.
- Discussion of emerging technologies for mutation detection and drug development.
Main Results:
- Targeted therapies are increasingly benefiting subsets of lung cancer patients.
- Drug resistance to current inhibitors (e.g., EGFR, ALK) is an inevitable clinical challenge.
- Technological advancements in early mutation detection and preclinical models show promise.
Conclusions:
- Despite challenges, targeted therapies represent a significant advancement in lung cancer care.
- Overcoming drug resistance requires sophisticated, multi-faceted therapeutic approaches.
- Future directions include improved early detection and novel drug development for sustained patient benefit.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies